DE69720745D1 - Therapeutische kombinationen von rar-antagonisten und rxr-agonisten - Google Patents

Therapeutische kombinationen von rar-antagonisten und rxr-agonisten

Info

Publication number
DE69720745D1
DE69720745D1 DE69720745T DE69720745T DE69720745D1 DE 69720745 D1 DE69720745 D1 DE 69720745D1 DE 69720745 T DE69720745 T DE 69720745T DE 69720745 T DE69720745 T DE 69720745T DE 69720745 D1 DE69720745 D1 DE 69720745D1
Authority
DE
Germany
Prior art keywords
rar
antagonist
therapeutic combinations
rxr agonists
rar antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69720745T
Other languages
English (en)
Other versions
DE69720745T2 (de
Inventor
Pierre Chambon
Hinrich Gronemeyer
R Reczek
Jacek Ostrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Louis Pasteur Strasbourg I
Institut National de la Sante et de la Recherche Medicale INSERM
Bristol Myers Squibb Co
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Louis Pasteur Strasbourg I
Institut National de la Sante et de la Recherche Medicale INSERM
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Louis Pasteur Strasbourg I, Institut National de la Sante et de la Recherche Medicale INSERM, Bristol Myers Squibb Co filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE69720745D1 publication Critical patent/DE69720745D1/de
Application granted granted Critical
Publication of DE69720745T2 publication Critical patent/DE69720745T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
DE69720745T 1996-08-28 1997-08-28 Therapeutische kombinationen von rar-antagonisten und rxr-agonisten Expired - Fee Related DE69720745T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2477296P 1996-08-28 1996-08-28
US24772P 1996-08-28
PCT/US1997/015155 WO1998008546A2 (en) 1996-08-28 1997-08-28 Therapeutic combinations of rar antagonists and rxr agonists and use thereof

Publications (2)

Publication Number Publication Date
DE69720745D1 true DE69720745D1 (de) 2003-05-15
DE69720745T2 DE69720745T2 (de) 2004-02-26

Family

ID=21822317

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69720745T Expired - Fee Related DE69720745T2 (de) 1996-08-28 1997-08-28 Therapeutische kombinationen von rar-antagonisten und rxr-agonisten

Country Status (11)

Country Link
US (2) US6130230A (de)
EP (1) EP0928200B1 (de)
JP (1) JP2001500486A (de)
AT (1) ATE236654T1 (de)
AU (1) AU731060B2 (de)
CA (1) CA2263817A1 (de)
DE (1) DE69720745T2 (de)
ES (1) ES2196361T3 (de)
IL (1) IL128723A0 (de)
NO (1) NO990912L (de)
WO (1) WO1998008546A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523166A (ja) 1998-09-29 2003-08-05 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
JP2003526677A (ja) * 2000-03-14 2003-09-09 ザ・ユニバーシテイ・オブ・ウエスタン・オンタリオ 骨形成に影響を与える組成物および方法
US20020090352A1 (en) * 2000-04-13 2002-07-11 Frederick Geissmann Compositions and methods for use in modulating immune system function
AU2001265039B2 (en) 2000-05-26 2007-03-29 Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by retinoids
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
JP2005500027A (ja) * 2001-06-11 2005-01-06 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ドーパミン分泌細胞の生存を増加させる方法
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (de) 2002-01-25 2006-06-07 Gamida Cell Ltd Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
GB2411115A (en) * 2004-02-19 2005-08-24 Medical Res Council Retinoic acid antagonists for the treatment of oesophageal disorders
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2181710A1 (de) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Liganden zur Modulation der Orphan-Rezeptor-Gamma (NR1F3) Aktivität
EP2329817A1 (de) * 2009-09-04 2011-06-08 Ernst-Moritz-Arndt-Universität Greifswald Retinsäurerezeptorantagonisten, miR-10a-Inhibitoren und Inhibitoren von HOXB1- und/oder HOXB3-Repressoren zur Behandlung von Bauchspeicheldrüsenkrebs
EP3616701A1 (de) 2011-06-24 2020-03-04 GRI Bio, Inc. Vorbeugung und behandlung entzündlicher erkrankungen
CA2863795A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
ES2909884T3 (es) 2013-08-20 2022-05-10 Univ Washington Through Its Center For Commercialization Inhibidores nuevos y específicos de la hidroxilasa del ácido retinoico del citocromo P450 26
WO2017091762A1 (en) 2015-11-25 2017-06-01 Io Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
AU2017278220C1 (en) 2016-06-10 2022-10-13 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
IL272013B2 (en) 2017-07-13 2024-03-01 Io Therapeutics Inc A combination of a rexinoid and retinoid substance with immunomodulatory properties and immunomodulatory substances for cancer treatment
CA3073953A1 (en) 2017-08-31 2019-03-07 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
US12115140B2 (en) * 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679899B2 (en) 1991-03-18 1997-07-17 Salk Institute For Biological Studies, The Response element compositions and assays employing same
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
EP0659045A4 (de) * 1993-05-18 1997-02-26 Inst Nat Sante Rech Med Gentechnologisch hergestellte mäuse, die veränderungen in den genen enthalten, welche retinoinsäure-rezeptor proteine kodieren.
US5702914A (en) * 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
EP0809509A4 (de) 1995-01-13 2000-02-02 Salk Inst For Biological Studi Allosterische regulation von nukleären hormonrezeptoren
US5747661A (en) * 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
US5559248A (en) * 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
AU5811298A (en) 1996-12-31 1998-07-31 Salk Institute For Biological Studies, The Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
AU5727998A (en) 1996-12-31 1998-07-31 Salk Institute For Biological Studies, The Treatment of liposarcomas using a combination of thiazolidinediones and retinoidx receptor selective agonists
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds

Also Published As

Publication number Publication date
JP2001500486A (ja) 2001-01-16
AU731060B2 (en) 2001-03-22
CA2263817A1 (en) 1998-03-05
NO990912L (no) 1999-04-27
US6130230A (en) 2000-10-10
EP0928200A2 (de) 1999-07-14
ATE236654T1 (de) 2003-04-15
US6653322B1 (en) 2003-11-25
AU4167497A (en) 1998-03-19
WO1998008546A2 (en) 1998-03-05
DE69720745T2 (de) 2004-02-26
WO1998008546A3 (en) 1998-04-23
ES2196361T3 (es) 2003-12-16
EP0928200B1 (de) 2003-04-09
WO1998008546A8 (en) 2001-04-19
NO990912D0 (no) 1999-02-25
IL128723A0 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
DE69720745D1 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE258067T1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
MA28008A1 (fr) Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
BR0008847A (pt) Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
DK0636027T3 (da) Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
IT1269185B (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
EA200200303A1 (ru) Синергетические комбинации антагониста рецептора nk1 и структурного аналога гамк
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
BR0309504A (pt) Método de tratamento, prevenção ou retardo de inìcio clìnico de neoplasma, composição, método de reduzir volume ou peso de tumor
ATE288756T1 (de) Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee